Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-810 in stable OTCD
NCT04442347Phase 1Completed
- Sponsor
- Arcturus Therapeutics
- Start
- Nov 2020
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ornithine transcarbamylase deficiency comparing ARCT-810 with Placebo (2 arms). Primary endpoint: Incidence, severity and dose-relationship of adverse events at 4 weeks. Started Nov 2020; status: completed.
02
Drugs
ARCT-810
03
Conditions
ornithine transcarbamylase deficiency
Beyond the preview
Go deeper on NCT04442347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04442347.